Publicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (4)

2015

  1. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

2010

  1. Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients

    Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50